MedTrace Logo

A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients

NCT01498081 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2012-10-26

No results posted yet for this study

Summary

This study in COPD patients will investigate the bronchodilatory effect of AZD2115. AZD2115 will be tested versus placebo and active comparators. The safety and tolerability of AZD2115 including investigations of clinically relevant systemically mediated effects will also be investigated.

Conditions

Interventions

DRUG

AZD2115

AZD2115 administered via inhalation

DRUG

Placebo

Placebo administered via inhalation

DRUG

Indacaterol

Indacaterol administered via inhalation

DRUG

Indacaterol + Tiotropium

Indacaterol + Tiotropium administered inhalation

Sponsors & Collaborators

Principal Investigators

  • Carin Jorup, MD · AstraZeneca R&D Molndal, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Poland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01498081 on ClinicalTrials.gov